Vident Advisory LLC Purchases 1,564 Shares of Zoetis Inc. (NYSE:ZTS)

Vident Advisory LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,482 shares of the company’s stock after purchasing an additional 1,564 shares during the period. Vident Advisory LLC’s holdings in Zoetis were worth $5,618,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZTS. Mission Wealth Management LP boosted its position in Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. grew its position in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares during the last quarter. HUB Investment Partners LLC raised its position in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Coppell Advisory Solutions LLC boosted its stake in shares of Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock valued at $68,000 after purchasing an additional 64 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators grew its holdings in shares of Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZTS. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Finally, UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $212.75.

Insiders Place Their Bets

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company’s stock.

Zoetis Trading Up 0.5%

NYSE ZTS opened at $163.90 on Tuesday. The stock has a market capitalization of $72.97 billion, a P/E ratio of 29.96, a P/E/G ratio of 2.78 and a beta of 0.94. The business has a 50 day simple moving average of $156.51 and a 200 day simple moving average of $165.09. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter last year, the firm posted $1.38 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.